So, do they Swan-Ganz anyone anymore, and if so, why?
This is one of the 3rd rails of medicine (meaning, there's no consensus).
The data do not support the claim that SG catheters reduce mortality. So, if that's your only factor in choosing an intervention or therapy (more on this below), then that would be that.
But, of course, there's more to the story. Many folks question the validity of applying the "benefit of reduced mortality" litmus test to something that is a monitoring device rather than a therapy. Others point out that a SG catheter might have more utility in the hands of an experienced operator, or at least someone who knows what to DO with the data.
There is no doubt that we use SG less now in my era (I'm a critical care fellow) then in times gone past (say, 10 years ago) at least in this country.
But I would also say that I do use them, and I feel like I have made clinical decisions based on the data. I work in multiple units stratified by specialty (SICU, MICU, CT ICU, Neuro ICU). I use them in the CT ICU commonly, the SICU occasionally, and the MICU and Neuro ICU rarely (in these last two units, almost exclusively in septic patients when I'm trying to make fluid balance decisions in the face of someone who might have the sepsis-associated transient decrease in cardiac function and I'm trying to decide if I need more resuscitation or more cardiac squeeze). Of course, I use them in pulm hypertensive patients if I'm actively titrating vasodilatory medications.
I think there is still a role for them. I'm using the LiDCO a lot, too.
Like most things in medicine, I feel the truth is somewhere in the middle: The catheter itself doesn't necessarily reduce mortality, but just because that has been the apparent result in academic studies, it shouldn't preclude an experienced (with SG catheters) intensivist using them in certain circumstances in certain patients. To be dogmatic about them one way or the other, I think, is the only mistake.